Sirolimus-exuding core-shell nanofibers as an implantable carrier for breast cancer therapy: preparation, characterization, in vitro cell studies, and in vivo anti-tumor activity.

MLA

Talimi, Rozhin, et al. “Sirolimus-Exuding Core-Shell Nanofibers as an Implantable Carrier for Breast Cancer Therapy: Preparation, Characterization, in Vitro Cell Studies, and in Vivo Anti-Tumor Activity.” Drug Development & Industrial Pharmacy, vol. 48, no. 12, Dec. 2022, pp. 694–707. EBSCOhost, https://doi.org/10.1080/03639045.2022.2161559.

APA

Talimi, R., Shahsavari, Z., Dadashzadeh, S., ten Hagen, T. L. M., & Haeri, A. (2022). Sirolimus-exuding core-shell nanofibers as an implantable carrier for breast cancer therapy: preparation, characterization, in vitro cell studies, and in vivo anti-tumor activity. Drug Development & Industrial Pharmacy, 48(12), 694–707. https://doi.org/10.1080/03639045.2022.2161559

Chicago

Talimi, Rozhin, Zahra Shahsavari, Simin Dadashzadeh, Timo L. M. ten Hagen, and Azadeh Haeri. 2022. “Sirolimus-Exuding Core-Shell Nanofibers as an Implantable Carrier for Breast Cancer Therapy: Preparation, Characterization, in Vitro Cell Studies, and in Vivo Anti-Tumor Activity.” Drug Development & Industrial Pharmacy 48 (12): 694–707. doi:10.1080/03639045.2022.2161559.